300501.SZ Stock Analysis
30
Avoid
Based on Eyestock quantitative analysis, 300501.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Shanghai Haishun New Pharmaceutical Packaging Co., Ltd. engages in the research, development, production, and sale of pharmaceutical packaging materials. The company is headquartered in Shanghai, Shanghai and currently employs 688 full-time employees. The company went IPO on 2016-02-04. The firm's major products include cold-forming composite hard sheet, polyterephthalate (PTP) aluminum foil and suppository (SP) films. Other products include polytrifluorochloroethylene (PTFCE) and polyvinyl chloride (PVC) composite hard sheet. Its products are widely used in the packaging of pharmaceutical, such as tablets, pills, capsules, granules, powders and suppositories, among others.